EUVIMEDEUVIMED entdecken
Zurückgezogene Publikation

Withdrawal: Serum DLAT Is a Potential Diagnostic Marker in AFP-Negative HCC

Fangfang Huang, Jindong Bai, Limei Hu, Changliang Luo, Leping Ning

Biological and Pharmaceutical Bulletin · 2024

DOI: 10.1248/bpb.b24-00516 ↗

Kurz gefasst

Zurückgezogene Publikation in der Zeitschrift Biological and Pharmaceutical Bulletin, 2024. Verfasst von Fangfang Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Biomarkers, Tumor, alpha-Fetoproteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study was to analyze dihydrolipoyllysine-residue acetyltransferase (DLAT) expression and diagnostic ability in hepatocellular carcinoma (HCC), assess its role in HCC growth, and factors affecting it. We conducted bioinformatics analyses, examined DLAT expression and prognosis in pre-cancer, and performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment studies while investigating its correlation with immunity. We also predicted regulatory factors, and detected DLAT in HCC cells using quantitative PCR (qPCR) and Western blotting, and in patient serum via enzyme-linked immunosorbent assay (ELISA). We found that DLAT was found to be upregulated in HCC and identified as an independent risk factor associated with immune cells. DLAT expression was regulated by hsa-miR-122-5p and the transcription factors zinc finger protein 148 (ZNF148), Myc-associated zinc-finger protein (MAZ), and Zinc finger and BTB domain-containing protein 12 (ZBTB12). Surprisingly, there was an increase in DLAT promoter methylation. The area under the receiver operating characteristic curves (AUCs) for serum DLAT in distinguishing HCC from healthy controls, high-risk individuals, and non-HCC cohorts were 0.905, 0.754, and 0.831, respectively. Combining DLAT with alpha-fetoprotein (AFP) improved diagnostic accuracy, with AUCs of 0.957, 0.819, 0.773, and 0.887 for the respective comparisons. Notably, serum DLAT was positive in 71.4% of AFP-negative HCC patients. And the transfection of hsa-miR-122-5p mimic could down regulate DLAT expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBiomarkers, Tumoralpha-FetoproteinsHumansFemaleMaleMiddle AgedMicroRNAsAcetyltransferasesCell Line, TumorGene Expression Regulation, NeoplasticDNA Methylation

Stichwörter der Autor:innen

alpha-fetoprotein (AFP)-negativediagnosisdihydrolipoamide S-acetyltransferasehepatocellular carcinoma (HCC)

Substanzen

Biomarkers, Tumoralpha-FetoproteinsMicroRNAsMIRN122 microRNA, humanAcetyltransferasesAFP protein, human

Autor:innen und Institutionen

  • Department of Laboratory Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences.

Zitieren

APA

Huang, F., Bai, J., Hu, L., Luo, C., & Ning, L. (2024). Withdrawal: Serum DLAT Is a Potential Diagnostic Marker in AFP-Negative HCC. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b24-00516

Vancouver

Huang F, Bai J, Hu L, Luo C, Ning L. Withdrawal: Serum DLAT Is a Potential Diagnostic Marker in AFP-Negative HCC. Biological and Pharmaceutical Bulletin. 2024. doi:10.1248/bpb.b24-00516

BibTeX
@article{Huang2024,
  author = {Huang, Fangfang and Bai, Jindong and Hu, Limei and Luo, Changliang and Ning, Leping},
  title = {Withdrawal: Serum DLAT Is a Potential Diagnostic Marker in AFP-Negative HCC},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2024},
  doi = {10.1248/bpb.b24-00516}
}
Kostenlos starten →